Could a lower aspirin dose calm the immune system without increasing bleeding?

NCT ID NCT03869268

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This completed study looked at how different doses of aspirin, given with or without another drug called ticagrelor, affect the body's immune response. Healthy volunteers took the medications for 10-14 days, then received an injection that causes temporary flu-like symptoms to test their immune reaction. The goal was to see if a lower, twice-daily aspirin dose might reduce inflammation while potentially lowering bleeding risk, which could help improve heart attack treatment.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Aspirin and ticagrelor
What this could lead to
If successful, this study could help doctors choose aspirin doses that reduce bleeding risk while still controlling inflammation after a heart attack.
What could go wrong
This is a small, early-phase study in healthy volunteers, not heart attack patients. The immune response to endotoxin may not reflect real-world outcomes, and results may not lead to changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, South Yorkshire, S5 7AU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.